WHO cautions use of dexamethasone as COVID-19 treatment; MM&M’s #CreateHealthEquity initiative; Hydroxychloroquine dropped from WHO’s study of coronavirus treatments.
Five things for pharma marketers to know: Thursday, June 11, 2020
Hydroxychloroquine study finds it does not prevent COVID-19 in exposed patients; Federal government picks five promising coronavirus vaccines; Gilead could earn $7 in revenue from remdesivir.
Five things for pharma marketers to know: Wednesday, June 3, 2020
Gilead develops easier-to-administer versions of Remdesivir; Pharma, agencies respond to George Floyd’s death; Social distancing most effective way to combat COVID-19.
Five things for pharma marketers to know: Tuesday, June 2, 2020
WHO says “vicious cycle” to occur if restrictions lifted too early; Bluebird BIO, BMS blood cancer cell therapy application refused by FDA; MM&M Convene COVID-19 takes place today.